stoxline Quote Chart Rank Option Currency Glossary
Amneal Pharmaceuticals, Inc. (AMRX)
4.66  0.35 (8.12%)    12-01 16:00
Open: 4.36
High: 4.69
Volume: 1,505,176
Pre. Close: 4.31
Low: 4.25
Market Cap: 1,428(M)
Technical analysis
2023-12-01 4:18:12 PM
Short term     
Mid term     
Targets 6-month :  5.47 1-year :  6.39
Resists First :  4.69 Second :  5.47
Pivot price 4.41
Supports First :  4.09 Second :  3.72
MAs MA(5) :  4.37 MA(20) :  4.36
MA(100) :  3.94 MA(250) :  2.85
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  66.4 D(3) :  53.3
RSI RSI(14): 61.8
52-week High :  4.73 Low :  1.24
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AMRX ] has closed below upper band by 1.5%. Bollinger Bands are 42.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.39 - 4.41 4.41 - 4.43
Low: 4.11 - 4.13 4.13 - 4.16
Close: 4.26 - 4.3 4.3 - 4.34
Company Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Headline News

Fri, 01 Dec 2023
Is Amneal Pharmaceuticals Inc (AMRX) a Stock to Watch After Gaining 1.55% This Week? - InvestorsObserver

Fri, 01 Dec 2023
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft ... - BioSpace

Tue, 28 Nov 2023
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt? - Simply Wall St

Sun, 26 Nov 2023
Amneal Pharmaceuticals Inc - (AMRX) Price Target Increased by ... - Nasdaq

Wed, 08 Nov 2023
Debevoise Advises Tarsadia Investments in Connection with the ... - Debevoise & Plimpton LLP

Wed, 08 Nov 2023
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2023 Earnings Call ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers—Specialty & Generic
Shares Out 307 (M)
Shares Float 124 (M)
Held by Insiders 11 (%)
Held by Institutions 64.7 (%)
Shares Short 3,190 (K)
Shares Short P.Month 3,850 (K)
Stock Financials
EPS 0.05
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.14
Profit Margin 0.4 %
Operating Margin 12.4 %
Return on Assets (ttm) 4.4 %
Return on Equity (ttm) 19 %
Qtrly Rev. Growth 13.6 %
Gross Profit (p.s.) 2.58
Sales Per Share 7.79
EBITDA (p.s.) 1.63
Qtrly Earnings Growth 0 %
Operating Cash Flow 186 (M)
Levered Free Cash Flow 158 (M)
Stock Valuations
PE Ratio 77.75
PEG Ratio -5.3
Price to Book value 2.17
Price to Sales 0.59
Price to Cash Flow 7.66
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android